Crossref Citations
This article has been cited by the following publications. This list is generated based on data provided by Crossref.
2004.
Current awareness: Pharmacoepidemiology and drug safety.
Pharmacoepidemiology and Drug Safety,
Vol. 13,
Issue. 5,
Ascher-Svanum, Haya
Stensland, Michael D.
Kinon, Bruce J.
and
Tollefson, Gary D.
2005.
Weight gain as a prognostic indicator of therapeutic improvement during acute treatment of schizophrenia with placebo or active antipsychotic.
Journal of Psychopharmacology,
Vol. 19,
Issue. 6_suppl,
p.
110.
Möller, Hans-Jürgen
2005.
Risperidone: a review.
Expert Opinion on Pharmacotherapy,
Vol. 6,
Issue. 5,
p.
803.
Bushe, Chris
and
Paton, Carol
2005.
The potential impact of antipsychotics on lipids in schizophrenia: is there enough evidence to confirm a link?.
Journal of Psychopharmacology,
Vol. 19,
Issue. 6_suppl,
p.
76.
Ascher-Svanum, Haya
Stensland, Michael
Zhao, Zhongyun
and
Kinon, Bruce J
2005.
Acute weight gain, gender, and therapeutic response to antipsychotics in the treatment of patients with schizophrenia.
BMC Psychiatry,
Vol. 5,
Issue. 1,
Ozcanli, Tuba
Erdogan, Ayten
Ozdemir, Samuray
Onen, Barış
Ozmen, Mine
Doksat, Kerem
and
Sonsuz, Abdullah
2006.
Severe liver enzyme elevations after three years of olanzapine treatment: A case report and review of olanzapine associated hepatotoxicity.
Progress in Neuro-Psychopharmacology and Biological Psychiatry,
Vol. 30,
Issue. 6,
p.
1163.
Cerqueira Filho, Edilberto Amorim de
Arandas, Fernanda de Sena
Oliveira, Irismar Reis de
and
Sena, Eduardo Pondé de
2006.
Dislipidemias e antipsicóticos atípicos.
Jornal Brasileiro de Psiquiatria,
Vol. 55,
Issue. 4,
p.
296.
Tarricone, Ilaria
Casoria, Michela
Gozzi, Beatrice Ferrari
Grieco, Daniela
Menchetti, Marco
Serretti, Alessandro
Ujkaj, Manjola
Pastorelli, Francesca
and
Berardi, Domenico
2006.
Metabolic risk factor profile associated with use of second generation antipsychotics: a cross sectional study in a community mental health centre.
BMC Psychiatry,
Vol. 6,
Issue. 1,
Bermudes, Richard A.
and
Guerdjikova, Anna
2006.
Obesity and Mental Disorders.
p.
165.
Monnelly, Edward P.
Fonda, Jennifer
Gagnon, David R.
Chittamooru, Subha
and
Lawler, Elizabeth V.
2015.
Weight Gain on Antipsychotic Medication Is Associated With Sustained Use Among Veterans With Schizophrenia.
Journal of Clinical Psychopharmacology,
Vol. 35,
Issue. 1,
p.
57.
Steen, Vidar M.
Skrede, Silje
Polushina, Tatiana
López, Miguel
Andreassen, Ole A.
Fernø, Johan
and
Hellard, Stephanie Le
2017.
Genetic evidence for a role of the SREBP transcription system and lipid biosynthesis in schizophrenia and antipsychotic treatment.
European Neuropsychopharmacology,
Vol. 27,
Issue. 6,
p.
589.
Raben, Alex T.
Marshe, Victoria S.
Chintoh, Araba
Gorbovskaya, Ilona
Müller, Daniel J.
and
Hahn, Margaret K.
2018.
The Complex Relationship between Antipsychotic-Induced Weight Gain and Therapeutic Benefits: A Systematic Review and Implications for Treatment.
Frontiers in Neuroscience,
Vol. 11,
Issue. ,
Kim, David D.
Barr, Alasdair M.
Fredrikson, Diane H.
Honer, William G.
and
Procyshyn, Ric M.
2019.
Association between Serum Lipids and Antipsychotic Response in Schizophrenia.
Current Neuropharmacology,
Vol. 17,
Issue. 9,
p.
852.
Garcia-Rizo, Clemente
2020.
Antipsychotic-Induced Weight Gain and Clinical Improvement: A Psychiatric Paradox.
Frontiers in Psychiatry,
Vol. 11,
Issue. ,
Rikhari, Praveen
Kumar, Ashutosh
Agrawal, Prabhat
and
Kumar, Harendra
2022.
Metabolic derangements with olanzapine and risperidone in schizophrenia spectrum and other psychotic disorders.
Journal of Family Medicine and Primary Care,
Vol. 11,
Issue. 5,
p.
2194.
Comments
No Comments have been published for this article.